asa guidelines on glp 1 New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review Glucagon-Like Peptide-1 Receptor Agonists in
Description
If GLP-1 RAs influence inflammatory pathways directly, their relevance could extend well beyond obesity management
Growing Advocacy : Medical and patient advocacy groups are pushing for obesity to be treated as a chronic condition, not a cosmetic issue, reinforcing the need for long-term, reimbursed care pathways
Exenatide must be injected subcutaneously (abdomen, thigh, or upper arm) twice daily prior to eating meals
Steven Johnson, and Dr
SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, carry the highest UTI risk of any diabetes medication class
